Skip to main content

Main menu

  • Home
  • Current Issue
  • Content
    • Current Issue
    • Early Access
    • Multimedia
    • Podcast
    • Collections
    • Past Issues
    • Articles by Subject
    • Articles by Type
    • Supplements
    • Plain Language Summaries
    • Calls for Papers
  • Info for
    • Authors
    • Reviewers
    • Job Seekers
    • Media
  • About
    • Annals of Family Medicine
    • Editorial Staff & Boards
    • Sponsoring Organizations
    • Copyrights & Permissions
    • Announcements
  • Engage
    • Engage
    • e-Letters (Comments)
    • Subscribe
    • Podcast
    • E-mail Alerts
    • Journal Club
    • RSS
    • Annals Forum (Archive)
  • Contact
    • Contact Us
  • Careers

User menu

  • My alerts

Search

  • Advanced search
Annals of Family Medicine
  • My alerts
Annals of Family Medicine

Advanced Search

  • Home
  • Current Issue
  • Content
    • Current Issue
    • Early Access
    • Multimedia
    • Podcast
    • Collections
    • Past Issues
    • Articles by Subject
    • Articles by Type
    • Supplements
    • Plain Language Summaries
    • Calls for Papers
  • Info for
    • Authors
    • Reviewers
    • Job Seekers
    • Media
  • About
    • Annals of Family Medicine
    • Editorial Staff & Boards
    • Sponsoring Organizations
    • Copyrights & Permissions
    • Announcements
  • Engage
    • Engage
    • e-Letters (Comments)
    • Subscribe
    • Podcast
    • E-mail Alerts
    • Journal Club
    • RSS
    • Annals Forum (Archive)
  • Contact
    • Contact Us
  • Careers
  • Follow annalsfm on Twitter
  • Visit annalsfm on Facebook
Research ArticleOriginal Research

Anticoagulants’ Safety and Effectiveness in General Practice: A Nationwide Prospective Cohort Study

Paul Frappé, Joël Cogneau, Yoann Gaboreau, Nathan Abenhaïm, Marc Bayen, Claude Guichard, Jean-Pierre Jacquet, François Lacoin, Sandra Liébart, Laurent Bertoletti, Jean-Luc Bosson and for the CACAO study investigators
The Annals of Family Medicine March 2020, 18 (2) 131-138; DOI: https://doi.org/10.1370/afm.2495
Paul Frappé
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: paul.frappe@univ-st-etienne.fr
Joël Cogneau
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoann Gaboreau
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathan Abenhaïm
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Bayen
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claude Guichard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Pierre Jacquet
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Lacoin
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra Liébart
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Bertoletti
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Luc Bosson
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

PURPOSE Most real-world studies on anticoagulants have been based on health insurance databases or performed in secondary care. The aim of this study was to compare safety and effectiveness between patients treated with vitamin K antagonists (VKAs) and patients treated with direct oral anticoagulants (DOACs) in a general practice setting.

METHODS The CACAO study (Comparison of Accidents and their Circumstances with Oral Anticoagulants) is a multicenter prospective cohort study conducted among ambulatory patients taking an oral anticoagulant. Participants were patients from the study’s cross-sectional phase receiving oral anticoagulants because of nonvalvular atrial fibrillation, for secondary prevention of venous thromboembolism, or both. They were followed as usual for 1 year by their general practitioners, who collected data on changes in therapy, thromboembolic events, bleeding, and deaths. All events were adjudicated by an independent committee. We used a propensity score and a Cox regression model to derive hazard ratios.

RESULTS Between April and December 2014, a total of 3,082 patients were included. At 1 year, 42 patients (1.7%) had experienced an arterial or venous event; 151 (6.1%) had experienced bleeding, including 47 (1.9%) who experienced major bleeding; and 105 (4.1%) had died. There was no significant difference between the VKA and DOAC groups regarding arterial or venous events, or major bleeding. The VKA group had a lower risk of overall bleeding (hazard ratio = 0.65; 95% CI, 0.43-0.98) but twice the risk of death (hazard ratio = 1.98; 95% CI, 1.15-3.42).

CONCLUSIONS VKAs and DOACs had fairly similar safety and effectiveness in general practice. The substantially higher incidence of deaths with VKAs is consistent with known data from health insurance databases and calls for further research to understand its cause.

Key words
  • anticoagulants
  • general practice
  • cohort studies
  • patient safety
  • medical records
  • primary care
  • practice-based research

INTRODUCTION

Oral anticoagulants are widely prescribed in general practice, where their main indications are atrial fibrillation and venous thromboembolic disease. These medications have well-proven effectiveness for those indications but are associated with increased bleeding risk.1 In ambulatory care, anticoagulants are involved in 12% of suspected adverse drug reactions and are the leading cause of emergency department admission for such reactions, because of bleeding.2,3

The pattern of anticoagulant prescribing is changing. Direct oral anticoagulants (DOACs) have been developed as an alternative to vitamin K antagonists (VKAs). Since their introduction in 2009, DOACs have accounted for a steadily increasing share of the total,4 reaching 38.0% among all patients receiving anticoagulants in France as of 2016.1 The many available medications have diverse pharmacokinetic and pharmacodynamic profiles, leading to different treatment choices, taking into account potential medication interactions and patients’ adherence, age, and renal function.1

Several real-world studies have provided results confirming those of phase 3 trials of DOACs, showing at least similar efficacy as VKAs and possibly better safety.1,5–14 Most of these studies, however, were based on health insurance databases, had a retrospective design, and were performed in secondary or tertiary care populations. Primary care clinicians continue to face practical issues in managing anticoagulant therapy, such as nonmajor bleeding, changes in anticoagulant therapy, patients’ individual history, and adherence.

The aim of this study was to compare safety and effectiveness between VKAs and DOACs in a general practice setting.

METHODS

The CACAO study (Comparison of Accidents and their Circumstances with Oral Anticoagulants) is a multicenter prospective observational cohort study conducted by general practitioners throughout France among unselected ambulatory patients receiving an oral anticoagulant. The 463 investigators from 391 practices cover 290 rural or urban towns, and are distributed over 47 counties of France.

Study Eligibility

We identified participants in phase 1 of the CACAO study for follow-up.15 In that first, cross-sectional phase, every patient aged 18 years or older taking an oral anticoagulant and consulting a general practitioner investigator, for any reason, was eligible. Patients receiving injectable anticoagulants and those younger than the age of 18 years were excluded. Each investigator enrolled all consecutive eligible patients for 3 months, beginning between April and October 2014. To be included in the phase 2 follow-up study, patients from phase 1 had to have a nonvalvular atrial fibrillation or thromboembolic indication for anticoagulation, and to need anticoagulation for more than 3 months. Among patients receiving an anticoagulant for more than 1 year, every patient receiving a DOAC was matched to 3 patients receiving VKAs on sex, age, indication for anticoagulation, duration of anticoagulant therapy, and renal function.

Data Collection

During 1 year of follow-up, patients received usual care from their general practitioner, without any mandatory appointments. Every 3 months, general practitioners collected data on bleeding events according to the International Society on Thrombosis and Haemostasis classification16,17; on the thrombotic of ischemic stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and acute coronary syndrome; on death; and on changes to anticoagulant therapy and the reasons for changes.

General practitioners also collected items for the CHA2DS2-VASc score (congestive heart failure, hypertension, age, diabetes, previous stroke/transient ischemic attack–vascular)18 and for the HAS-BLED score (hypertension, abnormal liver/renal function, stroke history, bleeding history or predisposition, labile international normalized ratio, elderly, drug/alcohol use).19 Both scores range from 0 to 9, with higher scores indicating greater risk for stroke (CHA2DS2-VASc) or major bleeding (HAS-BLED). These scores were automatically calculated.

Data were collected anonymously on an electronic case report form. All events were adjudicated by an independent committee.

Statistical Analysis

Characteristics of the study population are reported as numbers and percentages, with means and standard deviations. Comparisons were performed using the χ2 or Fisher exact test for categorical variables and the Student t test for continuous variables.

We calculated person-years of follow-up from the date of inclusion to the occurrence of first endpoint, death, or end of follow-up. Incidence rates were calculated as number of events divided by person-years. No imputation of missing data was planned.

Occurrence of death, arterial or venous events, and bleeding during the year of follow-up was analyzed with the Kaplan-Meier method. Incidence rates and hazard ratios (HRs) by anticoagulant class (VKA vs DOAC) were calculated with a Cox regression model. For arterial or venous events, and for hemorrhagic events, we used the Fine and Gray method20 to calculate absolute risk of events taking into account the competing risk of death.

To further compare VKA- and DOAC-treated patients, we performed a second matching using a propensity score. The propensity model included age (4 age groups) and sex; personal history of hypertension, DVT and/or PE, diabetes mellitus, symptomatic heart failure, peripheral arterial disease, bleeding requiring hospitalization, or cancer; Timed Up and Go test as estimated by the general practitioner; CHA2DS2-VASc score at the time of atrial fibrillation (0-1 vs ≥2); HAS-BLED score at the time of atrial fibrillation (≤3 vs >3); renal failure (present vs absent); indication for anticoagulation (2 classes); associated antiplatelet or nonsteroidal anti-inflammatory drug therapy; number of associated medications; duration of anti-coagulant treatment (≤1 year vs >1 year); patient adherence as perceived by the general practitioner (2 classes); and general practitioner sex and age (continuous variable). Patients for whom matching was not possible were excluded from the propensity analysis.

We performed analyses using Stata version 15.0 (StataCorp, LLC). A 2-sided P <.05 was considered significant.

Ethics

The CACAO study was approved by the ethical committee of the University Hospital of Saint-Etienne (IRBN112014/CHUSTE). Its protocol is registered with ClinicalTrials.gov (NCT02376777). All patients received written information about the study, emphasizing their right to decline participation or to withdraw at any time. No written informed consent was required for inclusion.

RESULTS

Between April and December 2014, the 463 general practitioners included 7,154 patients in the first phase of the study, of whom 3,082 were included in the follow-up phase: 1,946 patients (63.1%) were receiving a VKA and 1,136 patients (36.9%) were receiving a DOAC (Figure 1). Characteristics at the start of the follow-up phase were fairly well balanced between groups (Table 1).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Flow diagram for the CACAO study.

CACAO = Comparison of Accidents and their Circumstances with Oral Anticoagulants.

View this table:
  • View inline
  • View popup
Table 1

Characteristics of Patients at Start of Follow-Up (N = 3,082)

Overall, 11 patients (0.4%) were excluded from analysis because of missing data. Patients in the DOAC group as compared with counterparts in the VKA group more often had a definitive stopping of their anticoagulation (12.0% vs 6.9%; P < .001) and at least 1 switch of anticoagulant class (4.0% vs 2.2%; P = .005) (Table 2). Among those switching, DOAC recipients more commonly did so because of intolerance (17.8% vs 0%; P = .006) or altered renal function (26.7% vs 2.3%; P = .001).

View this table:
  • View inline
  • View popup
Table 2

Changes in Anticoagulation During Year of Follow-Up, by Anticoagulant Class at Start of Follow-Up (N = 3,071)

During the year of follow-up, 105 patients (4.1%) died; 151 (6.1%) experienced bleeding events, including 47 (1.9%) who experienced major bleeding events; and 42 (1.7%) experienced arterial or venous events: 14 ischemic strokes, 11 myocardial infarctions, 9 DVTs, 5 PEs, 3 transient ischemic attacks, and 1 arterial thrombosis of the lower limb. Relative to the DOAC group, the VKA group had a lower risk of any bleeding (HR = 0.67; 95% CI, 0.49-0.92) driven mainly by a lower risk of minor bleeding (HR = 0.49; 95% CI, 0.25-0.96), but a higher risk of death (HR = 2.37; 95% CI, 1.45-3.85) (Table 3).

View this table:
  • View inline
  • View popup
Table 3

One-Year Outcomes, by Anticoagulant Class at Outcome (N = 3,048; 2,641 Person-Years)

The propensity-matched analysis was based on 1,866 patients: 935 (50.1%) were receiving a VKA and 931 (49.9%) were receiving a DOAC (Table 4). The receiver operating characteristic curve model for the propensity model had an area under the curve of 0.675, indicating moderately good matching. Sixteen patients (0.9%) were excluded from analysis because of missing data. Relative to the DOAC group, the VKA group had a lower risk of any bleeding (HR = 0.65; 95% CI, 0.43-0.98) but a higher risk of death (HR = 1.98; 95% CI, 1.15-3.42) (Table 5).

View this table:
  • View inline
  • View popup
Table 4

Characteristics of Patients in the Propensity-Matched Sample (N = 1,882)

View this table:
  • View inline
  • View popup
Table 5

One-Year Outcomes in the Propensity-Matched Sample, by Anticoagulant Class at Outcome (N = 1,866; 1,618 Person-Years)

DISCUSSION

Main Findings

We report the results of the first French national prospective cohort study of ambulatory patients receiving oral anticoagulant therapy, a study designed and conducted by and for general practitioners. During the year of follow-up, about 2% of patients had an arterial or venous event; roughly 6% had bleeding, including 2% with major bleeding; and slightly more than 4% died. After propensity matching, there was no significant difference between patients receiving VKAs and patients receiving DOACs regarding arterial or venous events and major bleeding. The VKA group had a 35% lower risk of any bleeding but almost double the risk of all-cause mortality; the latter difference was not due to deaths from bleeding.

Comparison With Existing Literature

Our participants’ age and sex were similar to those of patients in previous cohort studies (mean age = 74 years in our cohort vs 70 years in previous cohorts; female = 45.2% vs 39% to 47%), but the rate of renal impairment was higher in our study (25.8% vs 4.5% to 10.1%).11,13,21 Risk scores vary widely in the previous literature: the proportion of patients with a CHA2DS2-VASc score of 2 or greater ranges from 59% to 90%, whereas it was 91.9% in our study, and the proportion with a HAS-BLED score of 3 or greater varies from 6.3% to 41%, whereas the proportion with a score exceeding 3 was 16.7% in our study.

Incidence rates were similar to those of cohorts studies for any bleeding (6.1% in our study vs 2.85% to 4.83% in previous studies), major bleeding (1.9% vs 1.12% to 4.04%), and mortality (4.1% vs 4.62% to 7.41%).11,13,21 All phase III trials and real-world cohort studies have shown a higher rate of death in VKA groups, but their hazard ratios were not always significant and were mostly smaller than ours,1,11,13,21–24 which was 1.98 (95% CI, 1.15-3.42). This elevated risk was mainly due to sudden deaths and deaths from malignancies, infections, and undetermined causes, and not to bleeding, suggesting it may stem from an external cause independent of anticoagulation therapy, such as our recruitment in primary care; other contextual factors missed in our matching process; or a lack of statistical power in our study.

Our VKA group had a lower risk of any bleeding compared with our DOAC group (HR = 0.65; 95% CI, 0.43-0.98), which differs from the finding in phase III trials and previous cohort studies.1,11,13, 21–24 This difference could be due to our recording of minor bleeding and to our prospective design, which allowed for possible declarative bias, as physicians were perhaps more suspicious and watchful for patients receiving DOACs because of the recent marketing of these drugs.

Strengths and Limitations

The multicenter nature and national size of our study may help improve the generalizability of its findings. Given that the investigator was the patient’s usual physician in 95% of cases, data were more readily accessible, permitting easy completion of the study form. In France, there are no anticoagulation clinics, and anticoagulation monitoring and international normalized ratio management are usually performed by general practitioners, limiting the impact of the absence of mandatory follow-up appointments. Data were collected from patients’ medical records, and there was no audit to verify that general practitioners did not miss any events. In France, however, patients have to register with a unique general practitioner or receive financial penalties, which limits that potential measurement bias. It is possible that physicians who agreed to participate in the study were more engaged in continuing medical education, medical research, and/or the anticoagulant topic than the average general practitioner. This possible recruitment bias should have a tendency to lead to underestimation of our outcomes, which are nevertheless important for practice. All events were adjudicated by a central committee, which reinforces the credibility of our results.

Given the context of continuing medical education of investigators, which imposed a minimum and a maximum cluster size, a complete initial matching was not possible. Inclusion of an average of just 4.8 patients per practice, however, obviated the need to adjust for clustering. The observed statistical power was low, especially regarding bleeding events and arteriovenous events. Propensity matching reduced the sample size but showed a good quality of the model (area under the curve = 0.675), which further reinforces our findings.

Conclusions

In this study, arteriovenous events and major bleeding events did not differ between patients receiving VKAs and patients receiving DOACs. The near doubling of mortality risk in the VKA group as compared with the DOAC group is consistent with known data from health insurance databases and calls for further research to explore its origin.

Acknowledgments

The authors are indebted to Claire Eychenne, Carole Rolland, and Céline Vermorel for their assistance in data management and analysis. We thank the members of the Primary Care Unit of the University of Geneva (Switzerland) for their editorial advice.

Footnotes

  • ↵* Investigators participating in the CACAO study are listed in Supplemental Appendix, available at http://www.AnnFamMed.org/content/18/2/131/suppl/DC1/.

  • Conflicts of interest: authors report none.

  • To read or post commentaries in response to this article, see it online at http://www.AnnFamMed.org/content/18/2/131.

  • Author affiliations: Department of General Practice, University of Saint-Etienne, Saint-Etienne, France (Frappé); Inserm UMR 1059, Sainbiose DVH, University of Saint-Etienne, Saint-Etienne, France (Frappé, Bertoletti); Inserm CIC-EC 1408, Saint-Etienne, France (Frappé, Bertoletti); Primary Care Unit, University of Geneva, Geneva, Switzerland (Frappé); Institut de Recherche en Médecine Générale, Paris, France (Cogneau, Abenhaïm, Guichard, Lacoin); Department of General Practice, Grenoble Alpes University, Grenoble, France (Gaboreau, Jacquet); TIMC-IMAG UMR 5525, Grenoble Alpes University, Grenoble, France (Gaboreau, Bosson); Department of General Practice, University of Lille, Lille, France (Bayen); Ambulatory Care Consultation Unit, CHU de Saint-Etienne, Saint-Etienne, France (Liébart); Department of Vascular Medicine and Therapeutics, CHU de Saint-Etienne, Saint-Etienne, France (Bertoletti).

  • Funding support: The CACAO study was supported by the French government (continuing professional development of investigators).

  • Disclaimer: The views expressed are solely those of the authors and do not necessarily represent official views of the authors’ affiliated institutions or funders.

  • Previous presentation: This work been presented at the Wonca World Conference; October 17-21, 2019; Seoul, Korea.

  • Clinical Trial Registration: ClinicalTrials.gov NCT02376777

  • Supplemental materials: Available at http://www.AnnFamMed.org/content/18/2/131/suppl/DC1/.

  • Received for publication December 10, 2018.
  • Revision received June 6, 2019.
  • Accepted for publication July 29, 2019.
  • © 2020 Annals of Family Medicine, Inc.

References

  1. ↵
    1. Haute autorité de santé. Commission de la transparence
    . Rapport d’évaluation des médicaments anticoagulants oraux [Evaluation report of oral anticoagulant drugs]. https://www.has-sante.fr/portail/upload/docs/application/pdf/2018-02/rapport_reev_aco_cteval234_2018-02-09_15-38-37_999.pdf. Published 2018. Accessed Feb 11, 2020.
  2. ↵
    1. Kane-Gill SL,
    2. Van Den Bos J,
    3. Handler SM
    . Adverse drug reactions in hospital and ambulatory care settings identified using a large administrative database. Ann Pharmacother. 2010; 44(6): 983–993.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Budnitz DS,
    2. Lovegrove MC,
    3. Shehab N,
    4. Richards CL
    . Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011; 365(21): 2002–2012.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Ten Cate V,
    2. Ten Cate H,
    3. Verheugt FWA
    . The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF): Exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands. Neth Heart J. 2016; 24(10): 574–580.
    OpenUrl
  5. ↵
    1. Graham DJ,
    2. Reichman ME,
    3. Wernecke M,
    4. et al
    . Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015; 131(2): 157–164.
    OpenUrlAbstract/FREE Full Text
    1. Kodani E,
    2. Atarashi H,
    3. Inoue H,
    4. Okumura K,
    5. Yamashita T,
    6. Origasa H,
    7. J-RHYTHM Registry Investigators
    . Beneficial effect of non-vitamin k antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation - results of the J-RHYTHM Registry 2. Circ J. 2016; 80(4): 843–851.
    OpenUrl
    1. Villines TC,
    2. Schnee J,
    3. Fraeman K,
    4. et al
    . A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost. 2015; 114(6): 1290–1298.
    OpenUrlCrossRefPubMed
    1. Seeger JD,
    2. Bykov K,
    3. Bartels DB,
    4. Huybrechts K,
    5. Zint K,
    6. Schneeweiss S
    . Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost. 2015; 114(6): 1277–1289.
    OpenUrlCrossRefPubMed
    1. López-López JA,
    2. Sterne JAC,
    3. Thom HHZ,
    4. et al
    . Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017; 359: j5058.
    OpenUrlAbstract/FREE Full Text
    1. Jun M,
    2. Lix LM,
    3. Durand M,
    4. et al.,
    5. Canadian Network for Observational Drug Effect Studies (CNODES) Investigators
    . Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study. BMJ. 2017; 359: j4323.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Larsen TB,
    2. Skjøth F,
    3. Nielsen PB,
    4. Kjældgaard JN,
    5. Lip GY
    . Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016; 353: i3189.
    OpenUrlAbstract/FREE Full Text
    1. Maura G,
    2. Blotière PO,
    3. Bouillon K,
    4. et al
    . Comparison of the short-term risk of bleeding and arterial thromboembolic events in non-valvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation. 2015; 132(13): 1252–1260.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Huisman MV,
    2. Rothman KJ,
    3. Paquette M,
    4. et al.,
    5. GLORIA-AF Investigators
    . Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry. Am Heart J. 2018; 198: 55–63.
    OpenUrl
  8. ↵
    1. Vinogradova Y,
    2. Coupland C,
    3. Hill T,
    4. Hippisley-Cox J
    . Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018; 362: k2505.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Frappé P,
    2. Cogneau J,
    3. Gaboreau Y,
    4. et al
    . Areas of improvement in anticoagulant safety. Data from the CACAO study, a cohort in general practice. PLoS One. 2017; 12(4): e0175167.
    OpenUrl
  10. ↵
    1. Kaatz S,
    2. Ahmad D,
    3. Spyropoulos AC,
    4. Schulman S,
    5. Subcommittee on Control of Anticoagulation
    . Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015; 13(11): 2119–2126.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Schulman S,
    2. Kearon C,
    3. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
    . Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3(4): 692–694.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Lip GY,
    2. Nieuwlaat R,
    3. Pisters R,
    4. Lane DA,
    5. Crijns HJ
    . Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010; 137(2): 263–272.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Pisters R,
    2. Lane DA,
    3. Nieuwlaat R,
    4. de Vos CB,
    5. Crijns HJ,
    6. Lip GY
    . A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138(5): 1093–1100.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Fine JP,
    2. Gray RJ
    . A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94(446): 496–509.
    OpenUrlCrossRef
  15. ↵
    1. Yao X,
    2. Abraham NS,
    3. Sangaralingham LR,
    4. et al
    . Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016; 5(6): e003725.
    OpenUrlAbstract/FREE Full Text
    1. Connolly SJ,
    2. Ezekowitz MD,
    3. Yusuf S,
    4. et al.,
    5. RE-LY Steering Committee and Investigators
    . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139–1151.
    OpenUrlCrossRefPubMed
    1. Patel MR,
    2. Mahaffey KW,
    3. Garg J,
    4. et al.,
    5. ROCKET AF Investigators
    . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–891.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Granger CB,
    2. Alexander JH,
    3. McMurray JJV,
    4. et al.,
    5. ARISTOTLE Committees and Investigators
    . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981–992.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Annals of Family Medicine: 18 (2)
The Annals of Family Medicine: 18 (2)
Vol. 18, Issue 2
March/April 2020
  • Table of Contents
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
  • In Brief
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Annals of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Anticoagulants’ Safety and Effectiveness in General Practice: A Nationwide Prospective Cohort Study
(Your Name) has sent you a message from Annals of Family Medicine
(Your Name) thought you would like to see the Annals of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Anticoagulants’ Safety and Effectiveness in General Practice: A Nationwide Prospective Cohort Study
Paul Frappé, Joël Cogneau, Yoann Gaboreau, Nathan Abenhaïm, Marc Bayen, Claude Guichard, Jean-Pierre Jacquet, François Lacoin, Sandra Liébart, Laurent Bertoletti, Jean-Luc Bosson, for the CACAO study investigators
The Annals of Family Medicine Mar 2020, 18 (2) 131-138; DOI: 10.1370/afm.2495

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Get Permissions
Share
Anticoagulants’ Safety and Effectiveness in General Practice: A Nationwide Prospective Cohort Study
Paul Frappé, Joël Cogneau, Yoann Gaboreau, Nathan Abenhaïm, Marc Bayen, Claude Guichard, Jean-Pierre Jacquet, François Lacoin, Sandra Liébart, Laurent Bertoletti, Jean-Luc Bosson, for the CACAO study investigators
The Annals of Family Medicine Mar 2020, 18 (2) 131-138; DOI: 10.1370/afm.2495
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Inappropriate direct oral anticoagulant prescriptions in patients with non-valvular atrial fibrillation: cross-sectional analysis of the French CACAO cohort study in primary care
  • Google Scholar

More in this TOC Section

  • Family-Based Interventions to Promote Weight Management in Adults: Results From a Cluster Randomized Controlled Trial in India
  • Teamwork Among Primary Care Staff to Achieve Regular Follow-Up of Chronic Patients
  • Shared Decision Making Among Racially and/or Ethnically Diverse Populations in Primary Care: A Scoping Review of Barriers and Facilitators
Show more Original Research

Similar Articles

Subjects

  • Domains of illness & health:
    • Chronic illness
  • Methods:
    • Quantitative methods
  • Other research types:
    • POEMs

Keywords

  • anticoagulants
  • general practice
  • cohort studies
  • patient safety
  • medical records
  • primary care
  • practice-based research

Content

  • Current Issue
  • Past Issues
  • Early Access
  • Plain-Language Summaries
  • Multimedia
  • Podcast
  • Articles by Type
  • Articles by Subject
  • Supplements
  • Calls for Papers

Info for

  • Authors
  • Reviewers
  • Job Seekers
  • Media

Engage

  • E-mail Alerts
  • e-Letters (Comments)
  • RSS
  • Journal Club
  • Submit a Manuscript
  • Subscribe
  • Family Medicine Careers

About

  • About Us
  • Editorial Board & Staff
  • Sponsoring Organizations
  • Copyrights & Permissions
  • Contact Us
  • eLetter/Comments Policy

© 2025 Annals of Family Medicine